Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nurtec in moderate plaque-type psoriasis
NCT04629950Phase 2
Key facts
- Status
- Completed
- Start
- Jan 2021
- Primary completion
- Aug 2024
- Countries
- 1
- Sponsor
- Weill Cornell Medicine
- Drugs
- rimegepant
- Conditions
- plaque psoriasis
01
Overview
Phase 2, randomised, double-blind trial of rimegepant in plaque psoriasis, sponsored by Weill Cornell Medicine. Started Jan 2021; status: completed.
02
Design
- Study design
- RandomizedDouble-blind
03
Results
Not all primary endpoints met
04
Registry description
The purpose of this study is to examine the use of a new investigational medication for the treatment of moderate plaque-type psoriasis. The study medication is rimegepant, an orally administered small molecule competitive inhibitor of the calcitonin gene-related peptide (CGRP) receptor. This medication, rimegepant, has been approved by the FDA under the trade name Nurtec for the treatment of acute migraine. However, rimegepant has not been studied in the treatment of moderate plaque-type psoriasis and is investigational for this indication.
Beyond the preview
Go deeper on NCT04629950.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04629950.